


A NEW SYNTHESIS OF DEGLYCO-BLEOMYCIN A2 AIMING AT THE
 TOTAL SYNTHESIS OF BLEOMYCIN

Sei-ichi Saito, Yoji Umezawa, Hajime Morishima,
 Tomohisa Takita, Hamao Umezawa*
 Institute of Microbial Chemistry
 Shinagawa-ku, Tokyo 141, Japan

Masatoshi Narita, Masami Otsuka, Susumu Kobayashi and Masaji Ohno
 Faculty of Pharmaceutical Sciences, University of Tokyo
 Bunkyo-ku, Tokyo 113, Japan

Summary: An improved route to synthesize deglyco-bleomycin A2, the aglycon of bleomycin A2, aiming at the total synthesis of bleomycin is described. The new route is characterized by the stepwise elongation of the amino acid constituents and the use of a thiol ester obtained by aldol condensation.


Deglyco-bleomycin A2, the aglycon of bleomycin (BLM) A2, is a hexapeptide consisting of five amino acids and a terminal amine¹⁾. Deglyco-BLM was found in the culture broth in a trace amount and also isolated from the mild acid hydrolyzate of BLM²⁾. The first total synthesis of deglyco-BLM A2³⁾, achieved by us, was based on the fragment condensation of the dipeptide (1-2) and tripeptide S³⁾ (3) followed by coupling with pyrimidoblamic acid (4).



amount of $\text{Cu}(\text{OAc})_2$ were needed for the condensation of the phenylthio ester **2a**. The resulting Boc- and Z-derivatives of tetrapeptide **5** were deprotected with 25% HBr-AcOH and $\text{CF}_3\text{CO}_2\text{H}$, respectively, and were chromatographed on CM-Sephadex C-25, pretreated with 0.05 M pH 7.1 sodium phosphate buffer, developed with a linear gradient of NaCl to give tetrapeptide **5** (**5**). The synthetic tetrapeptide **5** was identical with the natural sample⁵ in all respects (TLC, $^1\text{H-NMR}$, and optical rotation⁶).

Treatment of **5** with CH_3COCl in 6N HCl-AcOH (1:1) at room temperature afforded the di-O-acetyl derivative (**6**) (O-Ac: δ 2.74 and 2.49 in D_2O , external TMS reference) in 98% yield. Next, **6** was allowed to react with Boc- and Dnp-masked β -hydroxyhistidine (**7**)³ by DCC-HOBT in DMF to give a pentapeptide masked with Boc, Dnp and $\text{Ac}(\text{X}_2)$, (**8**)⁷, in 65% yield after purification by Sephadex LH-20 (developed with MeOH) and Amberlite XT-2 (developed with 50-80% MeOH) chromatographies. The Boc-group of **8** was removed by TFA (almost quantitative) and then allowed to react with Boc-masked pyrimidoblamic acid⁸ by DCC-HOBT in DMF to give deglyco-BLM A2 masked with Boc, Dnp and $\text{Ac}(\text{X}_2)$, (**10**)⁷, in 96% yield after purification by the Sephadex and Amberlite chromatographies. To confirm the structure of **10**, the protecting groups were removed by two steps: the Dnp- and Ac-groups were first removed by treatment with 0.5N NaOH-MeOH (1:1), followed with TFA to remove the Boc-group. The resulting deglyco-BLM A2 (**11**) was purified by CM-Sephadex C-25 chromatography as described previously³. The synthetic deglyco-BLM A2 thus obtained in 56% yield was identical with the natural sample² in all respects (TLC, $^1\text{H-NMR}$, and optical rotation⁹).

This new route to deglyco-BLM A2 not only gave a better overall yield than the previous one³, but also gave a starting material for the total synthesis of BLM A2 as described in the other paper¹⁰.



- 8 $\text{R}^1 = \text{Boc}$, $\text{R}^2 = \text{Dnp}$, $\text{R}^3 = \text{Ac}$
 9 $\text{R}^1 = \text{H}$, $\text{R}^2 = \text{Dnp}$, $\text{R}^3 = \text{Ac}$
 10 $\text{R}^1 = \text{Boc-pyrimidoblamyl}$, $\text{R}^2 = \text{Dnp}$, $\text{R}^3 = \text{Ac}$
 11 $\text{R}^1 = \text{pyrimidoblamyl}$, $\text{R}^2 = \text{R}^3 = \text{H}$ (deglyco-BLM A2)

References and Notes

- 1) The terminal amine was counted as one amino acid unit, since it is the decarboxylation derivative of amino acid.
- 2) Y. Muraoka, M. Suzuki, A. Fujii, Y. Umezawa, H. Naganawa, T. Takita, and H. Umezawa, *J. Antibiot.*, **34**, 353 (1981).
- 3) T. Takita, Y. Umezawa, S. Saito, H. Morishima, H. Umezawa, Y. Muraoka, M. Suzuki, M. Otsuka, S. Kobayashi, and M. Ohno, *Tetrahedron Lett.*, **22**, 671 (1981).
- 4) M. Narita, M. Otsuka, S. Kobayashi, M. Ohno, Y. Umezawa, H. Morishima, S. Saito, T. Takita, and H. Umezawa, *Tetrahedron Lett.*, preceding paper in this issue.
- 5) Y. Muraoka, T. Takita, K. Maeda, and H. Umezawa, *J. Antibiot.*, **25**, 185 (1972).
- 6) Data for optical rotations, $[\alpha]_{365\text{ nm}}^{20-21^\circ}$ (c 0.5-0.75, 0.1N HCl) of tetrapeptide S are as follows. Natural sample, -52° ; sample from 2a, -54° ; sample from 2b, -53° ; sample from 2c, -51° .
- 7) The compound is only stable under acidic and dark conditions. Therefore, the structure and purity were ensured only by $^1\text{H-NMR}$ in AcOH-d_4 .
- 8) Y. Umezawa, H. Morishima, S. Saito, T. Takita, H. Umezawa, S. Kobayashi, M. Otsuka, M. Narita, and M. Ohno, *J. Am. Chem. Soc.*, **102**, 6630 (1980).
- 9) Natural sample, $[\alpha]_{\text{D}}^{24}$ (c=0.5, 0.1N HCl) -15° ; synthetic sample, $[\alpha]_{\text{D}}^{22}$ (c=0.5, 0.1N HCl) -15° .
- 10) T. Takita, Y. Umezawa, S. Saito, H. Morishima, H. Naganawa, H. Umezawa, T. Tsuchiya, T. Miyake, S. Kageyama, S. Umezawa, Y. Muraoka, M. Suzuki, M. Otsuka, M. Narita, S. Kobayashi, and M. Ohno, *Tetrahedron Lett.*, preceding paper in this issue.

(Received in Japan 17 October 1981)